Precision cancer therapy effective in both children and adults

(Children's Hospital Los Angeles) Three quarters of patients, both adults and children, with a variety of advanced cancers occurring in different sites of the body responded to larotrectinib, a novel therapy that targets a specific genetic mutation. Results of a phase 1/2 trial have been published in the New England Journal of Medicine. Unlike most cancer therapies, this oral treatment is based on the genetic traits of the tumor and not the organ where the cancer originated.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

ConclusionsThis study provides mechanistic insights into the anticancer effect of WEGA through the regulation of macrophage polarization and highlights that WEGA could be a novel option for integrative cancer therapies.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
A popular oral medication used to treat blood clots is safe and effective for patients going through cancer therapy, a study says.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Publication date: Available online 3 December 2018Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Rebecca King, Nikki Tanna, Vinod PatelAbstractThe link between medication related osteonecrosis of the jaw (MRONJ) and bone modulating therapies such as bisphosphonates and denosumab is well established and the number of reported cases is increasing. The development of novel medications in cancer therapy, autoimmune and bone conditions has led to further cases of MRONJ being reported. However, in addition to this group of medications there are increasingly new agents in cancer therapy, such as ...
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
(Mayo Clinic) Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective. The drug was associated with fewer major bleeding events and fewer recurrent blood clots, compared to low-molecular- weight heparin. Their findings were presented at the annual meeting of the American Society of Hematology by Robert McBane II M.D., a Mayo Clinic cardiologist.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
The link between medication related osteonecrosis of the jaw (MRONJ) and bone modulating therapies such as bisphosphonates and denosumab is well established and the number of reported cases is increasing. The development of novel medications in cancer therapy, autoimmune and bone conditions has led to further cases of MRONJ being reported. However, in addition to this group of medications there are increasingly new agents in cancer therapy, such as anti-angiogenics agents that have now also been implicated in the development of MRONJ.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Source Type: research
SAN DIEGO ??Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective. The drug was associated with fewer major bleeding events and fewer recurrent blood clots, compared to low-molecular- weight heparin. Their findings were presented at the annual meeting of the [...]
Source: Mayo Clinic Minnesota News - Category: Hospital Management Source Type: news
Conclusions Therapy with IMed infusions in women with BC or gynecological cancer requires the same standards set for drug therapy. Although vitamins represent dietary supplements, appropriate assessment of the patient's medical history is needed and patients must receive appropriate information. For this purpose, standardized processes, as in the context of an IMed consultancy service, are helpful. PMID: 30498280 [PubMed]
Source: Geburtshilfe und Frauenheilkunde - Category: OBGYN Tags: Geburtshilfe Frauenheilkd Source Type: research
Conclusions: Ruxolitinib led to rapid and durable responses and was well tolerated in adult patients with secondary HLH.DisclosuresDevata: Affimed: Research Funding. Phillips: Abbvie: Research Funding; Pharmacyclics: Consultancy, Research Funding; Genentech: Consultancy; Bayer: Consultancy; Seattle Genetics: Consultancy; Gilead: Consultancy. Sood: Bayer: Research Funding. Wilcox: Incyte, Corp: Research Funding.
Source: Blood - Category: Hematology Authors: Tags: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I Source Type: research
ConclusionsBemcentinib is well tolerated in relapsed / refractory MDS and AML patients and exhibits anti-leukaemic activity. Furthermore, we observed a diversification of the TCR repertoire particularly in the bone marrow thereby supporting a role of AXL as immune checkpoint. Patient benefit was correlated with the level of the plasma marker soluble AXL at screening. This predictive biomarker candidate warrants further exploration in larger cohorts and has potential for development as companion diagnostics to select patient populations more likely to respond to bemcentinib treatment.DisclosuresLoges: BerGenBio: Consultancy...
Source: Blood - Category: Hematology Authors: Tags: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II Source Type: research
Background: Currently, low molecular weight heparin is the guideline endorsed treatment of patients with cancer associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, there are limited data supporting its use in cancer patients.Methods: Patients with cancer associated acute VTE were randomly assigned to receive either apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily or subcutaneous dalteparin (200 IU/kg for 1 month followed by 150 IU/kg once daily) for 6 months. The primary outcome was major bleeding. Secondary outcomes included VTE recurrence and a composite o...
Source: Blood - Category: Hematology Authors: Tags: 332. Antithrombotic Therapy: Management of Challenging Patients and Scenarios Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Children | Genetics | Hospitals | Oral Cancer